Question Bank › Better business coming in than going out

Better business coming in than going out

Better business coming in than going out: management describes the quality of new intake visibly exceeding what it is re

Calls Tested
483
Answered YES
22
Hit Rate
4.6%
rare by design

Cue Biopharma, Inc. (CUE) — this company's answers

NO on the Q3 2022 call 2022-11-14 D
The model's full reasoning — Q3 2022 call → NOWe need to determine if management conveys that the business being taken in now is of visibly higher quality than the business it is finishing/replacing, with both halves present: (1) an in-versus-out quality contrast stated by management, and (2) the turnover is real, current, and already in the numbers' future. Let's examine the transcript. The call is about Cue Biopharma, a biotech company. They discuss clinical trials, data, and pipeline. The concept of "business" here likely refers to the clinical programs, products, or perhaps partnerships. But the question is about incoming vs outgoing business quality. In biotech, this could be about new drug candidates vs old, or new indications vs old, or perhaps about the quality of the data from new trials vs old. However, the question specifically asks about "business the company is TAKING IN RIGHT NOW" vs "the business it is finishing, replacing, or letting run off". This could be about contracts, orders, customers, products, engagements. In a biotech context, it might be about the pipeline: new drug candidates (CUE-102) vs old (CUE-101)? Or perhaps about the quality of the patient population? But the question is about economic quality: better priced, better margined, better terms, longer duration, more valuable work, etc. Looking at the transcript, management talks about CUE-101 and CUE-102. They mention that CUE-102 shares 99% sequence identity with CUE-101, and that they were able to start at a higher dose due to derisking. They also talk about the platform being derisked. But is there a contrast between incoming and outgoing business? They talk about the data from CUE-101 monotherapy and combination, and they are excited about the potential. They also mention that they have treated first patient with CUE-102. But do they contrast the quality of the incoming business (e.g., CUE-102) against the outgoing (e.g., CUE-101)? Not really in terms of economics. They talk about the platform being derisked, which might imply that future candidates are cheaper to develop, but that's not about incoming vs outgoing business in the sense of orders or contracts. The question is about "business" as in revenue-generating activities. In biotech, revenue might come from partnerships, collaborations, or product sales. But here, they have collaboration revenue, but they don't discuss new contracts vs old.

← Back to the full CUE analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that the business the company is TAKING IN RIGHT NOW is of visibly HIGHER QUALITY than the business it is finishing, replacing, or letting run off — that is, does management contrast the character of its NEW incoming work, orders, contracts, customers, products, or engagements against the OLDER business still sitting in its reported results, and indicate that as the old naturally rolls off and the new becomes a bigger share, the company's results will improve on the strength of business ALREADY being taken in today? Answer YES when management's own words convey, in whatever form fits the industry, ONE coherent phenomenon with both halves present as a present-tense reality: (1) AN IN-VERSUS-OUT QUALITY CONTRAST, STATED BY MANAGEMENT. Management describes the business currently entering the company as better than what it is replacing — better priced, better margined, better terms, longer duration, more valuable work, stronger or higher-quality customers, a richer product or service mix, or otherwise economically superior — and makes the comparison against the company's OWN existing or outgoing book, not against competitors or the market. The forms vary widely: new orders or bookings coming in at better economics than the work being completed; new contracts, policies, leases, loans, or engagements written on better terms than those expiring; the sales mix of what is being sold now visibly richer than the mix still dominating reported results; lower-quality, lower-margin, or problematic business being deliberately allowed to run off while better business fills its place; or management explaining that what is in the backlog, book, or pipeline of committed work today carries better economics than what is currently being recognized. (2) THE TURNOVER IS REAL, CURRENT, AND ALREADY IN THE NUMBERS' FUTURE. The higher-quality intake must be described as actually being received, signed, booked, or written NOW — real transactions already happening, not aspirations to move upmarket or plans to improve mix — and management should convey, directly or plainly in substance, that reported results still largely reflect the older, lower-quality business, so the improvement arrives as the mix naturally turns over, without depending on new demand, market recovery, or events not yet secured. Answer NO if management discusses only overall demand strength, volume growth, or a good quarter without contrasting the quality of incoming business against outgoing. NO if the improvement in economics comes chiefly from raising prices to pass through costs, or from market prices moving favorably, rather than from a genuine change in the character of the business being taken in. NO if the better mix is only targeted, planned, or hoped for rather than already arriving. NO if the contrast is purely between a good quarter and a bad quarter, or between this company and competitors, rather than between the company's own incoming and outgoing business. NO if the new business's superiority is asserted only generically ("higher quality growth", "improving mix") with nothing concrete about what makes the incoming business better. NO if the reported results already fully reflect the better mix, with no meaningful turnover still ahead. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
BBD Banco Bradesco S.A. Q3 2022 2022-11-09 D
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
KTB Kontoor Brands, Inc. Q3 2021 2021-11-04 A
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
EHTH eHealth, Inc. Q2 2021 2021-07-29 F
ADSK Autodesk, Inc. Q3 2019 2018-11-20 A
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
T AT&T Inc. Q3 2018 2018-10-24 C+
ESS Essex Property Trust, Inc. Q2 2018 2018-08-03 B+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
HSTM HealthStream, Inc. Q3 2017 2017-10-24 C
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
BLKB Blackbaud, Inc. Q1 2017 2017-05-02 B+

How the model reasoned

HSTM · Q3 2017 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting incoming business against outgoing: - Patient Experience: "Existing clients also continue to convert from a phone modality to email and SMS text surveying modality... This conversion trend to continue... expected to have a positive impact... on patient experience margins." (lower price, higher margin shift already happening) - Provider Solutions: "the move from installed software sales to software as service sales... challenge revenue growth... but not profitability growth" and "backlog of unimplemented customers... significantly reduced" - Laerdal/HeartCode: "the new product we believe is right now based on contracts.
GFS · Q3 2021 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting the incoming business with the outgoing: compute revenue is declining "as expected" due to customers shifting to smaller nodes, while "newer high-margin customer designs" are ramping in 2H 2022 to offset it. They tie this directly to mix improvement from "d differentiated solutions become a larger portion" and "feature-rich" platforms (FDX, RF SOI, silicon photonics) growing while feature-rich CMOS is flat or down. LTAs signed now carry "pricing improvements" baked in for 2022+, with new agreements committing future capacity at those better terms.
CYBR · Q3 2021 → YESThe question is about whether management conveys that the new business they're taking in is of higher quality than the old business they're replacing, and that as the old rolls off, results will impro...YES Management explicitly contrasts the incoming subscription business (new logos, SaaS bookings, Privileged Cloud, EPM) as higher-quality than the outgoing perpetual license business it is replacing. They describe it as delivering “faster type of value,” “higher lifetime value over time,” and “more users and more products faster ,” while noting that the current revenue and profitability headwind from the mix shift is “obscuring the P&L” and that results will improve once the transition completes.

More from the question bank

Doing more and earning better on each oneFrom explaining to teachingBought-and-paid-for optionalityExit rate above the printCheck it yourselvesCompounding order flowAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.